Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2006 1
2018 1
2019 1
2021 4
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI.
Hoffmann E, Gerwing M, Niland S, Niehoff R, Masthoff M, Geyer C, Wachsmuth L, Wilken E, Höltke C, Heindel WL, Hoerr V, Schinner R, Berger P, Vogl T, Eble JA, Maus B, Helfen A, Wildgruber M, Faber C. Hoffmann E, et al. Among authors: wilken e. J Immunother Cancer. 2023 Mar;11(3):e006092. doi: 10.1136/jitc-2022-006092. J Immunother Cancer. 2023. PMID: 36918222 Free PMC article.
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: wilken ee. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).
Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Jensen BV, Wilken EE, Geertsen P, Behrens C, Nolsoe C, Hermann KL, Svane IM, Nielsen D. Chen IM, et al. Among authors: wilken ee. J Clin Oncol. 2022 Sep 20;40(27):3180-3189. doi: 10.1200/JCO.21.02511. Epub 2022 Apr 27. J Clin Oncol. 2022. PMID: 35476508 Clinical Trial.
Resolving immune cells with patrolling behaviour by magnetic resonance time-lapse single cell tracking.
Masthoff M, Freppon FN, Zondler L, Wilken E, Wachsmuth L, Niemann S, Schwarz C, Fredrich I, Havlas A, Block H, Gerwing M, Helfen A, Heindel W, Zarbock A, Wildgruber M, Faber C. Masthoff M, et al. Among authors: wilken e. EBioMedicine. 2021 Nov;73:103670. doi: 10.1016/j.ebiom.2021.103670. Epub 2021 Nov 4. EBioMedicine. 2021. PMID: 34742131 Free PMC article.
Single-isocenter stereotactic non-coplanar arc treatment of 200 patients with brain metastases: multileaf collimator size and setup uncertainties.
Calmels L, Blak Nyrup Biancardo S, Sibolt P, Nørring Bekke S, Bjelkengren U, Wilken E, Geertsen P, Sjöström D, Behrens CF. Calmels L, et al. Among authors: wilken e. Strahlenther Onkol. 2022 May;198(5):436-447. doi: 10.1007/s00066-021-01846-6. Epub 2021 Sep 15. Strahlenther Onkol. 2022. PMID: 34528112 Free PMC article.
14 results